ΔNp73, TAp73 and Δ133p53 Extracellular Vesicle Cargo as Early Diagnosis Markers in Colorectal Cancer

• Published in: Cancers Vol. 13; no. 9; p. 2240
• Main Authors: Rodríguez-Cobos, Javier, Viñal, David, Poves, Carmen, Fernández-Aceñero, María J, Peinado, Héctor, Pastor-Morate, Daniel, Prieto, Mª Isabel, Barderas, Rodrigo, Rodríguez-Salas, Nuria, Domínguez, Gemma
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 07-05-2021; MDPI
• Subjects: Biomarkers; Biopsy; Cancer; Colonoscopy; Colorectal cancer; Colorectal carcinoma; Diagnosis; Extracellular vesicles; Lesions; Medical screening; mRNA; Plasma; Software; Statistical analysis; Survival analysis; Spain; early diagnosis; Δ133p53; TAp73; colorectal cancer; extracellular vesicles; ΔNp73; screening programs; biomarkers; premalignant lesions; liquid biopsy
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers13092240

The early diagnosis of colorectal cancer is a key factor in the overall survival of the patients. The actual screening programs include different approaches with significant limitations such as unspecificity, high invasiveness, and detection at late stages of the disease. The specific content of extracellular vesicles derived from malignant cells may represent a non-invasive technique for the early detection of colorectal cancer. Here, we studied the mRNA levels of ΔNp73, TAp73, and Δ133p53 in plasma-derived extracellular vesicles from healthy subjects (
= 29), individuals with premalignant lesions (
= 49), and colorectal cancer patients (
= 42). Extracellular vesicles' ΔNp73 levels were already significantly high in subjects with premalignant lesions. Δ133p53 levels were statistically increased in colorectal cancer patients compared to the other two groups and were associated with patients' survival. Remarkably, TAp73 mRNA was not detected in any of the individuals. The evaluation of ΔNp73, Δ133p53 and CEA sensitivity, specificity and AUC values supports ΔNp73 as a better early diagnosis biomarker and CEA as the best to identify advanced stages. Thus, low levels of CEA and a high content of ΔNp73 may identify in screening programs those individuals at higher risk of presenting a premalignant lesion. In addition, Δ133p53 emerges as a potential prognosis biomarker in colorectal cancer.